mouse il-27 Search Results


  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93
    Boster Bio anti mouse
    Anti Mouse, supplied by Boster Bio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti mouse/product/Boster Bio
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti mouse - by Bioz Stars, 2021-04
    93/100 stars
      Buy from Supplier

    94
    Thermo Fisher mouse il 27
    Mouse Il 27, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse il 27/product/Thermo Fisher
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    mouse il 27 - by Bioz Stars, 2021-04
    94/100 stars
      Buy from Supplier

    86
    r&d systems il 27
    <t>IL-27</t> regulates inflammatory mediators during primary pulmonary N. brasiliensis infection. ( A ) In vivo comparison of selected cytokines and chemokines of Il27ra −/− mice and wild type control (C57BL/6NJ) mice to primary N. brasiliensis infection (L3 n=500/mouse) in the lungs (BALF) at 2 days after infection. ( B ) C57BL/6J mice administered with rmIL-27 (100 ng/mouse i.p., once daily on day 0 and day 1) or mock control (0.1% BSA in PBS) during N. brasiliensis infection and analyzed for the presence of inflammatory mediators after 2 days p.i in BALF. All data were obtained by multiplexed bead-based assay (Luminex-200). Graphs (A-B) are presented as mean ± SEM, were analyzed by two-tailed t-test and each circle indicates an individual mouse, * P
    Il 27, supplied by r&d systems, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/il 27/product/r&d systems
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    il 27 - by Bioz Stars, 2021-04
    86/100 stars
      Buy from Supplier

    94
    R&D Systems recombinant mouse il 27
    <t>IL-27</t> does not directly suppress macrophage CXCL2 expression To investigate the mechanism of IL-27 mediated immunosuppression, chemokine response in bone marrow derived macrophage (BMDM) ( a–c ), thioglycollate induced peritoneal macrophage (TPM) ( d e ) and colonic lamina propria F4/80 + macrophage ( f ) were assessed. ( a ) > 90% of M-CSF cultured bone marrow derived cells expressed F4/80 and IL-27Rα. ( b ) BMDM were stimulated for 5 hours with various concentrations of LPS as labelled +/− rIL27 (100ng/ml) and CXCL2 measured in supernatant by ELISA. Combined data from several experiments, generated from > 3 wells/experimental condition. LPS resulted in a robust CXCL2 response but there was no differential response in association with IL-27, t-test. ( c ) Exposure for > 48 hours prior to LPS stimulation did not impact CXCL2 response, t-test. ( d ) Peritoneal cell phenotype day 4 post IP thioglycollate injection. Cells expressed IL-27Rα. ( e ) Adherent cells were stimulated with 50ng/ml of LPS +/− 100ng/ml rIL27, for 5 or 72 hours. Again, LPS resulted in a robust CXCL2 response but there was no differential response in association with IL-27. ( f ) This was also seen in ex vivo colonic lamina propria F4/80+ cells stimulated for 24 hours with 50ng/ml of LPS +/− 100ng/ml rIL27, t-test. Results in C, E F presented from one experiment, with the same pattern of expression seen in repeat experiment. All data presented as mean + SEM.
    Recombinant Mouse Il 27, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant mouse il 27/product/R&D Systems
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    recombinant mouse il 27 - by Bioz Stars, 2021-04
    94/100 stars
      Buy from Supplier

    N/A
    The Mouse IL 17D Antibody from R D Systems is a rat monoclonal antibody to IL 17D This antibody reacts with mouse The Mouse IL 17D Antibody has been validated
      Buy from Supplier

    N/A
    The IL 17D antibody from Proteintech is a mouse monoclonal antibody to a fusion protein of human IL 17D This antibody recognizes human antigen The IL 17D antibody has been
      Buy from Supplier

    Image Search Results


    IL-27 regulates inflammatory mediators during primary pulmonary N. brasiliensis infection. ( A ) In vivo comparison of selected cytokines and chemokines of Il27ra −/− mice and wild type control (C57BL/6NJ) mice to primary N. brasiliensis infection (L3 n=500/mouse) in the lungs (BALF) at 2 days after infection. ( B ) C57BL/6J mice administered with rmIL-27 (100 ng/mouse i.p., once daily on day 0 and day 1) or mock control (0.1% BSA in PBS) during N. brasiliensis infection and analyzed for the presence of inflammatory mediators after 2 days p.i in BALF. All data were obtained by multiplexed bead-based assay (Luminex-200). Graphs (A-B) are presented as mean ± SEM, were analyzed by two-tailed t-test and each circle indicates an individual mouse, * P

    Journal: bioRxiv

    Article Title: IL-27 enhances the lymphocyte mediated innate resistance to primary hookworm infection in the lungs

    doi: 10.1101/2020.08.12.248021

    Figure Lengend Snippet: IL-27 regulates inflammatory mediators during primary pulmonary N. brasiliensis infection. ( A ) In vivo comparison of selected cytokines and chemokines of Il27ra −/− mice and wild type control (C57BL/6NJ) mice to primary N. brasiliensis infection (L3 n=500/mouse) in the lungs (BALF) at 2 days after infection. ( B ) C57BL/6J mice administered with rmIL-27 (100 ng/mouse i.p., once daily on day 0 and day 1) or mock control (0.1% BSA in PBS) during N. brasiliensis infection and analyzed for the presence of inflammatory mediators after 2 days p.i in BALF. All data were obtained by multiplexed bead-based assay (Luminex-200). Graphs (A-B) are presented as mean ± SEM, were analyzed by two-tailed t-test and each circle indicates an individual mouse, * P

    Article Snippet: A multiplex bead-based immunoassay (Cytokine & Chemokine 26-Plex Mouse ProcartaPlex™ Panel 1, Thermo Fisher Scientific) was used for simultaneous quantification of the following cytokines/chemokines: IL-1β, IL-2, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12p70, IL-13, IL-17A, IL-18, IL-22, IL-23, IL-27, GROα (CXCL-1), IP-10 (CXCL-10), MCP-1 (CCL-2), MCP-3 (CCL-7), MIP-1α (CCL-3), MIP-1β (CCL-4), MIP-2 (CXCL-2), RANTES (CCL-5), Eotaxin (CCL-11), GM-CSF, IFN gamma, and TNF alpha ( ).

    Techniques: Infection, In Vivo, Mouse Assay, Bead-based Assay, Luminex, Two Tailed Test

    IL-27 enhances innate resistance to primary N. brasiliensis infection in the lungs. ( A-C ) In vivo comparison of susceptibility of Il27ra −/− mice and wild type (WT; C57BL/6NJ) mice to primary N. brasiliensis infection (L3 n=500/mouse) in the lungs at 2 days after infection. ( A ) Alveolar parasite burden, ( B ) alveolar hemorrhage, and ( C ) alveolar total protein in BALF. ( D - F ) In vivo comparison of susceptibility of WT mice (C57BL/6J) administered with rmIL-27 (100 ng/mouse i.p., once daily on days 0-1) or mock control (0.1% BSA in PBS) during N. brasiliensis infection and analyzed after 2 days p.i. ( D ) Comparison of alveolar parasite burden, ( E ) alveolar hemorrhage, and ( F ) alveolar total protein in BALF. Data (A-F) are shown as mean ± SEM and each circle indicates an individual mouse, * P

    Journal: bioRxiv

    Article Title: IL-27 enhances the lymphocyte mediated innate resistance to primary hookworm infection in the lungs

    doi: 10.1101/2020.08.12.248021

    Figure Lengend Snippet: IL-27 enhances innate resistance to primary N. brasiliensis infection in the lungs. ( A-C ) In vivo comparison of susceptibility of Il27ra −/− mice and wild type (WT; C57BL/6NJ) mice to primary N. brasiliensis infection (L3 n=500/mouse) in the lungs at 2 days after infection. ( A ) Alveolar parasite burden, ( B ) alveolar hemorrhage, and ( C ) alveolar total protein in BALF. ( D - F ) In vivo comparison of susceptibility of WT mice (C57BL/6J) administered with rmIL-27 (100 ng/mouse i.p., once daily on days 0-1) or mock control (0.1% BSA in PBS) during N. brasiliensis infection and analyzed after 2 days p.i. ( D ) Comparison of alveolar parasite burden, ( E ) alveolar hemorrhage, and ( F ) alveolar total protein in BALF. Data (A-F) are shown as mean ± SEM and each circle indicates an individual mouse, * P

    Article Snippet: A multiplex bead-based immunoassay (Cytokine & Chemokine 26-Plex Mouse ProcartaPlex™ Panel 1, Thermo Fisher Scientific) was used for simultaneous quantification of the following cytokines/chemokines: IL-1β, IL-2, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12p70, IL-13, IL-17A, IL-18, IL-22, IL-23, IL-27, GROα (CXCL-1), IP-10 (CXCL-10), MCP-1 (CCL-2), MCP-3 (CCL-7), MIP-1α (CCL-3), MIP-1β (CCL-4), MIP-2 (CXCL-2), RANTES (CCL-5), Eotaxin (CCL-11), GM-CSF, IFN gamma, and TNF alpha ( ).

    Techniques: Infection, In Vivo, Mouse Assay

    Cytokines and chemokines in brochoalveolar lavage fluids after treatment with recombinant mouse IL-27. In vivo comparison of mediators in BALF from WT mice (C57BL/6J) administered with rmIL-27 (100 ng/mouse i.p.) or mock control (0.1% BSA in PBS) on day 0 and day 1 of N. brasiliensis infection and analyzed after 2 days p.i. Data are shown as mean ± SEM and each circle indicates an individual mouse, two-tailed t-test, * P

    Journal: bioRxiv

    Article Title: IL-27 enhances the lymphocyte mediated innate resistance to primary hookworm infection in the lungs

    doi: 10.1101/2020.08.12.248021

    Figure Lengend Snippet: Cytokines and chemokines in brochoalveolar lavage fluids after treatment with recombinant mouse IL-27. In vivo comparison of mediators in BALF from WT mice (C57BL/6J) administered with rmIL-27 (100 ng/mouse i.p.) or mock control (0.1% BSA in PBS) on day 0 and day 1 of N. brasiliensis infection and analyzed after 2 days p.i. Data are shown as mean ± SEM and each circle indicates an individual mouse, two-tailed t-test, * P

    Article Snippet: A multiplex bead-based immunoassay (Cytokine & Chemokine 26-Plex Mouse ProcartaPlex™ Panel 1, Thermo Fisher Scientific) was used for simultaneous quantification of the following cytokines/chemokines: IL-1β, IL-2, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12p70, IL-13, IL-17A, IL-18, IL-22, IL-23, IL-27, GROα (CXCL-1), IP-10 (CXCL-10), MCP-1 (CCL-2), MCP-3 (CCL-7), MIP-1α (CCL-3), MIP-1β (CCL-4), MIP-2 (CXCL-2), RANTES (CCL-5), Eotaxin (CCL-11), GM-CSF, IFN gamma, and TNF alpha ( ).

    Techniques: Recombinant, In Vivo, Mouse Assay, Infection, Two Tailed Test

    IL-27 does not directly suppress macrophage CXCL2 expression To investigate the mechanism of IL-27 mediated immunosuppression, chemokine response in bone marrow derived macrophage (BMDM) ( a–c ), thioglycollate induced peritoneal macrophage (TPM) ( d e ) and colonic lamina propria F4/80 + macrophage ( f ) were assessed. ( a ) > 90% of M-CSF cultured bone marrow derived cells expressed F4/80 and IL-27Rα. ( b ) BMDM were stimulated for 5 hours with various concentrations of LPS as labelled +/− rIL27 (100ng/ml) and CXCL2 measured in supernatant by ELISA. Combined data from several experiments, generated from > 3 wells/experimental condition. LPS resulted in a robust CXCL2 response but there was no differential response in association with IL-27, t-test. ( c ) Exposure for > 48 hours prior to LPS stimulation did not impact CXCL2 response, t-test. ( d ) Peritoneal cell phenotype day 4 post IP thioglycollate injection. Cells expressed IL-27Rα. ( e ) Adherent cells were stimulated with 50ng/ml of LPS +/− 100ng/ml rIL27, for 5 or 72 hours. Again, LPS resulted in a robust CXCL2 response but there was no differential response in association with IL-27. ( f ) This was also seen in ex vivo colonic lamina propria F4/80+ cells stimulated for 24 hours with 50ng/ml of LPS +/− 100ng/ml rIL27, t-test. Results in C, E F presented from one experiment, with the same pattern of expression seen in repeat experiment. All data presented as mean + SEM.

    Journal: Inflammatory bowel diseases

    Article Title: Interleukin 27 is a potential rescue therapy for acute severe colitis via interleukin-10 dependent, T cell independent attenuation of colonic mucosal innate immune responses

    doi: 10.1097/MIB.0000000000001274

    Figure Lengend Snippet: IL-27 does not directly suppress macrophage CXCL2 expression To investigate the mechanism of IL-27 mediated immunosuppression, chemokine response in bone marrow derived macrophage (BMDM) ( a–c ), thioglycollate induced peritoneal macrophage (TPM) ( d e ) and colonic lamina propria F4/80 + macrophage ( f ) were assessed. ( a ) > 90% of M-CSF cultured bone marrow derived cells expressed F4/80 and IL-27Rα. ( b ) BMDM were stimulated for 5 hours with various concentrations of LPS as labelled +/− rIL27 (100ng/ml) and CXCL2 measured in supernatant by ELISA. Combined data from several experiments, generated from > 3 wells/experimental condition. LPS resulted in a robust CXCL2 response but there was no differential response in association with IL-27, t-test. ( c ) Exposure for > 48 hours prior to LPS stimulation did not impact CXCL2 response, t-test. ( d ) Peritoneal cell phenotype day 4 post IP thioglycollate injection. Cells expressed IL-27Rα. ( e ) Adherent cells were stimulated with 50ng/ml of LPS +/− 100ng/ml rIL27, for 5 or 72 hours. Again, LPS resulted in a robust CXCL2 response but there was no differential response in association with IL-27. ( f ) This was also seen in ex vivo colonic lamina propria F4/80+ cells stimulated for 24 hours with 50ng/ml of LPS +/− 100ng/ml rIL27, t-test. Results in C, E F presented from one experiment, with the same pattern of expression seen in repeat experiment. All data presented as mean + SEM.

    Article Snippet: Recombinant mouse IL-27 (NSO expressed, R & D systems, 2799-010/CF) was added to stimulation assay media as appropriate at 100ng/ml.

    Techniques: Expressing, Derivative Assay, Cell Culture, Enzyme-linked Immunosorbent Assay, Generated, Injection, Ex Vivo

    IL-27 is associated with phosphorylated STAT-1 in colonic epithelial cells and significantly reduces pro-inflammatory cytokine profile in vivo ( a ) Immunohistochemistry for phosphorylated STAT-1 (Tyr701). Multifocal mucosal epithelial cells and scattered inflammatory cells within the lamina propria and submucosa show strong positive nuclear labeling for phosphorylated STAT-1 in response to oral LL-IL-27. Occasional cells show both strong nuclear and variable cytoplasmic labeling. There is no phosphorylated STAT-1 immunopositivity in colitic mice who received no treatment or treatment with LL-C. Diaminobenzidine chromogen and hematoxylin counterstain. This pattern of expression was seen in all mice per group (n=3). ( b ) Cytokine gene expression profile in distal colon homogenate was assessed by Taqman RT-PCR assays (Applied Biosystems) and analyzed with ddCt method of relative quantification; normalization to endogenous GAPDH control and level of expression compared to ethanol control group. Data, combined from 2 experiments, presented as mean + SEM. Il6 (p=0.003), Il1b (p=0.001) and Tnf (p=

    Journal: Inflammatory bowel diseases

    Article Title: Interleukin 27 is a potential rescue therapy for acute severe colitis via interleukin-10 dependent, T cell independent attenuation of colonic mucosal innate immune responses

    doi: 10.1097/MIB.0000000000001274

    Figure Lengend Snippet: IL-27 is associated with phosphorylated STAT-1 in colonic epithelial cells and significantly reduces pro-inflammatory cytokine profile in vivo ( a ) Immunohistochemistry for phosphorylated STAT-1 (Tyr701). Multifocal mucosal epithelial cells and scattered inflammatory cells within the lamina propria and submucosa show strong positive nuclear labeling for phosphorylated STAT-1 in response to oral LL-IL-27. Occasional cells show both strong nuclear and variable cytoplasmic labeling. There is no phosphorylated STAT-1 immunopositivity in colitic mice who received no treatment or treatment with LL-C. Diaminobenzidine chromogen and hematoxylin counterstain. This pattern of expression was seen in all mice per group (n=3). ( b ) Cytokine gene expression profile in distal colon homogenate was assessed by Taqman RT-PCR assays (Applied Biosystems) and analyzed with ddCt method of relative quantification; normalization to endogenous GAPDH control and level of expression compared to ethanol control group. Data, combined from 2 experiments, presented as mean + SEM. Il6 (p=0.003), Il1b (p=0.001) and Tnf (p=

    Article Snippet: Recombinant mouse IL-27 (NSO expressed, R & D systems, 2799-010/CF) was added to stimulation assay media as appropriate at 100ng/ml.

    Techniques: In Vivo, Immunohistochemistry, Labeling, Mouse Assay, Expressing, Reverse Transcription Polymerase Chain Reaction

    Oral delivery of IL-27 leads to improved histological colitis score and protection against ulceration in acute severe colitis ( a ) Cumulative histological colitis score based on 5 parameters (degree of inflammatory cell infiltrate/ mucosal ulceration/ crypt hyperplasia/ goblet cell depletion, presence of granuloma) with a maximum of 14. TNBS+LL-C vs. TNBS+ LL-IL-27, p=0.035. ( b ) Degree of distal colonic mucosa ulceration score, graded on a scale of 0–4. 0=none, 1=erosion, 2=mild ulceration, 3=moderate ulceration, 4=severe ulceration. TNBS+LL-C vs. TNBS+ LL-IL-27, p=0.008. Data generated from randomly selected animals from 2 experiments. n=5,5,6,7 for ethanol, TNBS, TNBS+LL-C and TNBS+LL-IL27, respectively. Mean + SEM. ( c ) Epithelial proliferation index was assessed by Ki67 immunohistochemistry on paraffin embedded distal colon sections. n=5/group from 2 experiments. Index derived from number of Ki67 positive cells/total number epithelial cells/ HPF, expressed as percentage. Mean + SEM % from 5 HPF per sample used in analysis. Colitis evoked a significant increase in proliferation index across all groups compared to ethanol control; p=0.009, 0.001 0.002 for TNBS alone, +LL-C and +LL-IL-27, respectively. There was no significant difference between TNBS alone vs. +LL-C vs. +LL-IL-27 (p=0.243), t-test. ( d ) Representative distal colon photomicrographs of each experimental group. There is full-thickness necrosis of the mucosa and marked submucosal inflammation and edema in both the TNBS alone and TNBS+LL-C treated mice. LL-IL-27 treatment significantly reduced mucosal necrosis and decreased inflammatory infiltrates. Slides were optically scanned with an Aperio AT2 digital slide scanner. Hematoxylin and eosin staining.

    Journal: Inflammatory bowel diseases

    Article Title: Interleukin 27 is a potential rescue therapy for acute severe colitis via interleukin-10 dependent, T cell independent attenuation of colonic mucosal innate immune responses

    doi: 10.1097/MIB.0000000000001274

    Figure Lengend Snippet: Oral delivery of IL-27 leads to improved histological colitis score and protection against ulceration in acute severe colitis ( a ) Cumulative histological colitis score based on 5 parameters (degree of inflammatory cell infiltrate/ mucosal ulceration/ crypt hyperplasia/ goblet cell depletion, presence of granuloma) with a maximum of 14. TNBS+LL-C vs. TNBS+ LL-IL-27, p=0.035. ( b ) Degree of distal colonic mucosa ulceration score, graded on a scale of 0–4. 0=none, 1=erosion, 2=mild ulceration, 3=moderate ulceration, 4=severe ulceration. TNBS+LL-C vs. TNBS+ LL-IL-27, p=0.008. Data generated from randomly selected animals from 2 experiments. n=5,5,6,7 for ethanol, TNBS, TNBS+LL-C and TNBS+LL-IL27, respectively. Mean + SEM. ( c ) Epithelial proliferation index was assessed by Ki67 immunohistochemistry on paraffin embedded distal colon sections. n=5/group from 2 experiments. Index derived from number of Ki67 positive cells/total number epithelial cells/ HPF, expressed as percentage. Mean + SEM % from 5 HPF per sample used in analysis. Colitis evoked a significant increase in proliferation index across all groups compared to ethanol control; p=0.009, 0.001 0.002 for TNBS alone, +LL-C and +LL-IL-27, respectively. There was no significant difference between TNBS alone vs. +LL-C vs. +LL-IL-27 (p=0.243), t-test. ( d ) Representative distal colon photomicrographs of each experimental group. There is full-thickness necrosis of the mucosa and marked submucosal inflammation and edema in both the TNBS alone and TNBS+LL-C treated mice. LL-IL-27 treatment significantly reduced mucosal necrosis and decreased inflammatory infiltrates. Slides were optically scanned with an Aperio AT2 digital slide scanner. Hematoxylin and eosin staining.

    Article Snippet: Recombinant mouse IL-27 (NSO expressed, R & D systems, 2799-010/CF) was added to stimulation assay media as appropriate at 100ng/ml.

    Techniques: Generated, Immunohistochemistry, Derivative Assay, Mouse Assay, Staining

    An active inflammatory microenvironment is required for oral IL-27 to suppress inflammation in the colonic mucosa Pre-exposure to LL-IL-27 (10 oral gavages over 2 week period) prior to intra-rectal instillation of 2mg TNBS (SJL/J 6–8 week old male mice) did not impact acute colitis induction as measured by ( a ) disease activity index, ( b ) weight loss from starting weight, or ( c ) macroscopic colitis score (colon length and weight). Data presented combined from 2 separate experiments, n=10/group, as mean + SEM; ANOVA on Ranks Rank Sum test for pairwise comparisons.

    Journal: Inflammatory bowel diseases

    Article Title: Interleukin 27 is a potential rescue therapy for acute severe colitis via interleukin-10 dependent, T cell independent attenuation of colonic mucosal innate immune responses

    doi: 10.1097/MIB.0000000000001274

    Figure Lengend Snippet: An active inflammatory microenvironment is required for oral IL-27 to suppress inflammation in the colonic mucosa Pre-exposure to LL-IL-27 (10 oral gavages over 2 week period) prior to intra-rectal instillation of 2mg TNBS (SJL/J 6–8 week old male mice) did not impact acute colitis induction as measured by ( a ) disease activity index, ( b ) weight loss from starting weight, or ( c ) macroscopic colitis score (colon length and weight). Data presented combined from 2 separate experiments, n=10/group, as mean + SEM; ANOVA on Ranks Rank Sum test for pairwise comparisons.

    Article Snippet: Recombinant mouse IL-27 (NSO expressed, R & D systems, 2799-010/CF) was added to stimulation assay media as appropriate at 100ng/ml.

    Techniques: Mouse Assay, Activity Assay

    Oral IL-27 reduces colonic neutrophil infiltrate associated with decreased CXC chemokine expression Distal colon inflammatory cell phenotype assessed by immunohistochemistry using ( a ) myeloperoxidase (MPO) and ( b ) F4/80 positivity to identify neutrophils and macrophages, respectively. Data generated from randomly selected animals from 2 experiments. n=5,5,6,6,8 for untreated, ethanol, TNBS, TNBS+LL-C and TNBS+LL-IL-27, respectively. Mean + SEM. ( a ) Treatment with IL-27 led to a significant reduction in MPO + neutrophil infiltration into the colonic mucosa (p=0.002, t-test). ( b ) F4/80 + macrophage infiltrate did not alter with LL-IL-27 treatment (p=0.250, t-test). ( c ) On day 2 post TNBS instillation, CXCL1 and CXCL2 but not CXCL5 protein (measured by ELISA and normalized to mg total protein concentration) were significantly reduced in distal colon homogenate in colitic mice treated with LL-IL-27 compared to LL-C (p=0.026, p=0.038 p=0.427 (t-test), respectively). Data represents mean + SEM, generated from 2 separate experiments, n=10 /group. ( d ) This IL-27 associated reduction in CXCL2 expression persisted as measured later in the experimental protocol (day 4 or time of death), p=0.001 and p=0.003, compared to TNBS plus LL-C and TNBS alone, respectively. Mean + SEM, generated from one experiment, n=3, 3, 8, 8, 11 for untreated, ethanol, TNBS, TNBS+LL-C and TNBS+LL-IL27, respectively. ( e ) Ex-vivo derived colitis associated lamina propria F4/80 + macrophage cells secreted CXCL2 measured by ELISA after 24 hours culture at 37°C (10 5 cells/200µl), and this was significantly reduced in cells exposed in vivo to LL-IL-27, p=0.001 (t-test). Data generated from 5 pooled distal colon samples per group.

    Journal: Inflammatory bowel diseases

    Article Title: Interleukin 27 is a potential rescue therapy for acute severe colitis via interleukin-10 dependent, T cell independent attenuation of colonic mucosal innate immune responses

    doi: 10.1097/MIB.0000000000001274

    Figure Lengend Snippet: Oral IL-27 reduces colonic neutrophil infiltrate associated with decreased CXC chemokine expression Distal colon inflammatory cell phenotype assessed by immunohistochemistry using ( a ) myeloperoxidase (MPO) and ( b ) F4/80 positivity to identify neutrophils and macrophages, respectively. Data generated from randomly selected animals from 2 experiments. n=5,5,6,6,8 for untreated, ethanol, TNBS, TNBS+LL-C and TNBS+LL-IL-27, respectively. Mean + SEM. ( a ) Treatment with IL-27 led to a significant reduction in MPO + neutrophil infiltration into the colonic mucosa (p=0.002, t-test). ( b ) F4/80 + macrophage infiltrate did not alter with LL-IL-27 treatment (p=0.250, t-test). ( c ) On day 2 post TNBS instillation, CXCL1 and CXCL2 but not CXCL5 protein (measured by ELISA and normalized to mg total protein concentration) were significantly reduced in distal colon homogenate in colitic mice treated with LL-IL-27 compared to LL-C (p=0.026, p=0.038 p=0.427 (t-test), respectively). Data represents mean + SEM, generated from 2 separate experiments, n=10 /group. ( d ) This IL-27 associated reduction in CXCL2 expression persisted as measured later in the experimental protocol (day 4 or time of death), p=0.001 and p=0.003, compared to TNBS plus LL-C and TNBS alone, respectively. Mean + SEM, generated from one experiment, n=3, 3, 8, 8, 11 for untreated, ethanol, TNBS, TNBS+LL-C and TNBS+LL-IL27, respectively. ( e ) Ex-vivo derived colitis associated lamina propria F4/80 + macrophage cells secreted CXCL2 measured by ELISA after 24 hours culture at 37°C (10 5 cells/200µl), and this was significantly reduced in cells exposed in vivo to LL-IL-27, p=0.001 (t-test). Data generated from 5 pooled distal colon samples per group.

    Article Snippet: Recombinant mouse IL-27 (NSO expressed, R & D systems, 2799-010/CF) was added to stimulation assay media as appropriate at 100ng/ml.

    Techniques: Expressing, Immunohistochemistry, Generated, Enzyme-linked Immunosorbent Assay, Protein Concentration, Mouse Assay, T-Test, Ex Vivo, Derivative Assay, In Vivo

    IL-27 immunosuppression in acute TNBS colitis is T cell-independent and IL-10-dependent, evoking early IL-10 secretion in the colonic mucosa (a–d) 4mg TNBS instilled intra-rectally into Rag −/− mice. Data combined from 2 separate experiments. n=10/group. There was a significant difference in ( a ) DAI in mice treated with LL-IL-27 compared to LL-C on day 1 and 2, p=0.013 p=0.040 respectively, t-test, and ( b ) degree of weight loss from baseline on day 1 (p=0.019), then a trend just under significance on days 2 3 (p=0.06), t-test. ( c ) Distal colon homogenate CXCL2 protein was significantly reduced with LL-IL-27, p=0.028, ( d ) as was distal colon histology score, p=0.028, t-test. ( e–h ) 6mg TNBS instilled intra-rectally into IL-10 −/− mice. Data combined from 2 separate experiments. n=8/group. ( e ) DAI, p=0.237, 0.903, 0.681, respectively on day 1, 2 3, LL-IL-27 vs. LL-C, t-test, ( f ) weight loss from baseline, p=0.727, 0.751, 0.716, respectively on day 1, 2 and 3, LL-IL-27 vs. LL-C, t-test. ( g ) CXCL2 protein in distal colon homogenate, p=0.959 and ( h ) distal colon histology score, p=0.608, t-test, were not significantly different in mice treated with LL-IL-27 compared to LL-C. ( i ) On day 2 post TNBS instillation in SJL/J mice, there was a significant increase in distal colon IL-10 protein associated with IL-27, p=0.01, t-test. ( j ) Later in the treatment protocol, at day 4 or time of death, this difference in IL-10 protein expression was not apparent, p=0.653. At both time points, n=10/group, combined data from 2 experiments.

    Journal: Inflammatory bowel diseases

    Article Title: Interleukin 27 is a potential rescue therapy for acute severe colitis via interleukin-10 dependent, T cell independent attenuation of colonic mucosal innate immune responses

    doi: 10.1097/MIB.0000000000001274

    Figure Lengend Snippet: IL-27 immunosuppression in acute TNBS colitis is T cell-independent and IL-10-dependent, evoking early IL-10 secretion in the colonic mucosa (a–d) 4mg TNBS instilled intra-rectally into Rag −/− mice. Data combined from 2 separate experiments. n=10/group. There was a significant difference in ( a ) DAI in mice treated with LL-IL-27 compared to LL-C on day 1 and 2, p=0.013 p=0.040 respectively, t-test, and ( b ) degree of weight loss from baseline on day 1 (p=0.019), then a trend just under significance on days 2 3 (p=0.06), t-test. ( c ) Distal colon homogenate CXCL2 protein was significantly reduced with LL-IL-27, p=0.028, ( d ) as was distal colon histology score, p=0.028, t-test. ( e–h ) 6mg TNBS instilled intra-rectally into IL-10 −/− mice. Data combined from 2 separate experiments. n=8/group. ( e ) DAI, p=0.237, 0.903, 0.681, respectively on day 1, 2 3, LL-IL-27 vs. LL-C, t-test, ( f ) weight loss from baseline, p=0.727, 0.751, 0.716, respectively on day 1, 2 and 3, LL-IL-27 vs. LL-C, t-test. ( g ) CXCL2 protein in distal colon homogenate, p=0.959 and ( h ) distal colon histology score, p=0.608, t-test, were not significantly different in mice treated with LL-IL-27 compared to LL-C. ( i ) On day 2 post TNBS instillation in SJL/J mice, there was a significant increase in distal colon IL-10 protein associated with IL-27, p=0.01, t-test. ( j ) Later in the treatment protocol, at day 4 or time of death, this difference in IL-10 protein expression was not apparent, p=0.653. At both time points, n=10/group, combined data from 2 experiments.

    Article Snippet: Recombinant mouse IL-27 (NSO expressed, R & D systems, 2799-010/CF) was added to stimulation assay media as appropriate at 100ng/ml.

    Techniques: Mouse Assay, Expressing

    Oral delivery of IL-27 suppresses acute severe colitis ( a ) LL-IL-27 evokes a decreased disease activity index (DAI) compared to LL-C; 5.8 vs. 8.2 on day 1, 5.3 vs. 8.9 on day 2 and 4.1 vs. 8.2, on day 3, maximum 12, *p=0.001. ( b ) LL-IL-27 led to significantly less weight loss than TNBS+LL-C or TNBS alone, p

    Journal: Inflammatory bowel diseases

    Article Title: Interleukin 27 is a potential rescue therapy for acute severe colitis via interleukin-10 dependent, T cell independent attenuation of colonic mucosal innate immune responses

    doi: 10.1097/MIB.0000000000001274

    Figure Lengend Snippet: Oral delivery of IL-27 suppresses acute severe colitis ( a ) LL-IL-27 evokes a decreased disease activity index (DAI) compared to LL-C; 5.8 vs. 8.2 on day 1, 5.3 vs. 8.9 on day 2 and 4.1 vs. 8.2, on day 3, maximum 12, *p=0.001. ( b ) LL-IL-27 led to significantly less weight loss than TNBS+LL-C or TNBS alone, p

    Article Snippet: Recombinant mouse IL-27 (NSO expressed, R & D systems, 2799-010/CF) was added to stimulation assay media as appropriate at 100ng/ml.

    Techniques: Activity Assay